Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESKA: Anakinra in Non-COVID-19 ARDS
2024-518125-15-00Phase 2Authorised
- Sponsor
- Azienda sanitaria universitaria Friuli Centrale
- Start
- Nov 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of anakinra in acute respiratory distress syndrome (ARDS), sponsored by Azienda sanitaria universitaria Friuli Centrale. Primary endpoint: Ventilation-free days. Planned start Nov 2024; status: authorised.
02
Drugs
anakinra
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2024-518125-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518125-15-00.